Mural Oncology Plc Stock Current Valuation

MURA Stock   3.92  0.03  0.76%   
Valuation analysis of Mural Oncology plc helps investors to measure Mural Oncology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Mural Oncology's Enterprise Value Over EBITDA is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.77, whereas Enterprise Value is projected to grow to (171.6 M). Fundamental drivers impacting Mural Oncology's valuation include:
Price Book
0.4056
Enterprise Value
-95.3 M
Undervalued
Today
3.92
Please note that Mural Oncology's price fluctuation is slightly risky at this time. Calculation of the real value of Mural Oncology plc is based on 3 months time horizon. Increasing Mural Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Mural Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mural Stock. However, Mural Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  3.92 Real  6.8 Target  16.33 Hype  3.84 Naive  4.21
The real value of Mural Stock, also known as its intrinsic value, is the underlying worth of Mural Oncology plc Company, which is reflected in its stock price. It is based on Mural Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Mural Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
6.80
Real Value
10.35
Upside
Estimating the potential upside or downside of Mural Oncology plc helps investors to forecast how Mural stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mural Oncology more accurately as focusing exclusively on Mural Oncology's fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-2.05-1.96-1.86
Details
Hype
Prediction
LowEstimatedHigh
0.293.847.39
Details
Naive
Forecast
LowNext ValueHigh
0.674.217.76
Details
3 Analysts
Consensus
LowTarget PriceHigh
14.8616.3318.13
Details

Mural Oncology plc Company Current Valuation Analysis

Mural Oncology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Mural Oncology Current Valuation

    
  (95.33 M)  
Most of Mural Oncology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mural Oncology plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Mural Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Mural Oncology is extremely important. It helps to project a fair market value of Mural Stock properly, considering its historical fundamentals such as Current Valuation. Since Mural Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mural Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mural Oncology's interrelated accounts and indicators.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Mural Oncology plc has a Current Valuation of (95.33 Million). This is 100.66% lower than that of the Biotechnology sector and 102.05% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.57% higher than that of the company.

Mural Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mural Oncology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mural Oncology could also be used in its relative valuation, which is a method of valuing Mural Oncology by comparing valuation metrics of similar companies.
Mural Oncology is currently under evaluation in current valuation category among its peers.

Mural Oncology ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mural Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mural Oncology's managers, analysts, and investors.
Environmental
Governance
Social

Mural Fundamentals

About Mural Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mural Oncology plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mural Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mural Oncology plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock:
Check out Mural Oncology Piotroski F Score and Mural Oncology Altman Z Score analysis.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.02)
Return On Assets
(0.81)
Return On Equity
(1.78)
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.